Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.04 Million USD | 11.64% |
| 2022 | -5.7 Million USD | 10.48% |
| 2021 | -6.37 Million USD | -18.74% |
| 2020 | -5.37 Million USD | 15.71% |
| 2019 | -6.37 Million USD | 14.47% |
| 2018 | -7.44 Million USD | -2.02% |
| 2017 | -7.3 Million USD | -20.69% |
| 2016 | -6.05 Million USD | -10.81% |
| 2015 | -5.46 Million USD | -18.4% |
| 2014 | -4.61 Million USD | -164.29% |
| 2013 | -1.74 Million USD | -4666.26% |
| 2012 | -36.61 Thousand USD | -626.84% |
| 2011 | -5037.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.49 Million USD | -12.47% |
| 2024 Q2 | -876.74 Thousand USD | 41.34% |
| 2024 Q3 | -1.02 Million USD | -16.51% |
| 2023 Q1 | -1.27 Million USD | 11.48% |
| 2023 Q2 | -1.42 Million USD | -11.74% |
| 2023 FY | -5.04 Million USD | 11.64% |
| 2023 Q3 | -1.01 Million USD | 28.84% |
| 2023 Q4 | -1.32 Million USD | -31.01% |
| 2022 Q2 | -1.75 Million USD | -15.97% |
| 2022 FY | -5.7 Million USD | 10.48% |
| 2022 Q4 | -1.44 Million USD | -43.12% |
| 2022 Q1 | -1.5 Million USD | 12.47% |
| 2022 Q3 | -1 Million USD | 42.49% |
| 2021 Q1 | -1.26 Million USD | 6.77% |
| 2021 Q4 | -1.72 Million USD | -3.41% |
| 2021 FY | -6.37 Million USD | -18.74% |
| 2021 Q2 | -1.75 Million USD | -38.6% |
| 2021 Q3 | -1.66 Million USD | 4.72% |
| 2020 Q3 | -1.24 Million USD | -7.55% |
| 2020 Q1 | -1.61 Million USD | -6.25% |
| 2020 Q2 | -1.15 Million USD | 28.71% |
| 2020 Q4 | -1.35 Million USD | -9.11% |
| 2020 FY | -5.37 Million USD | 15.71% |
| 2019 Q3 | -1.57 Million USD | -4.31% |
| 2019 Q4 | -1.52 Million USD | 3.05% |
| 2019 FY | -6.37 Million USD | 14.47% |
| 2019 Q1 | -1.76 Million USD | 20.85% |
| 2019 Q2 | -1.5 Million USD | 14.73% |
| 2018 Q2 | -2.01 Million USD | -27.27% |
| 2018 FY | -7.44 Million USD | -2.02% |
| 2018 Q4 | -2.23 Million USD | -37.85% |
| 2018 Q3 | -1.62 Million USD | 19.55% |
| 2018 Q1 | -1.58 Million USD | 15.9% |
| 2017 Q4 | -1.88 Million USD | -2.19% |
| 2017 FY | -7.3 Million USD | -20.69% |
| 2017 Q1 | -1.37 Million USD | 22.87% |
| 2017 Q2 | -2.2 Million USD | -60.19% |
| 2017 Q3 | -1.84 Million USD | 16.47% |
| 2016 Q1 | -1.27 Million USD | 19.86% |
| 2016 FY | -6.05 Million USD | -10.81% |
| 2016 Q4 | -1.78 Million USD | -2.95% |
| 2016 Q3 | -1.73 Million USD | -38.09% |
| 2016 Q2 | -1.25 Million USD | 1.94% |
| 2015 Q2 | -1.25 Million USD | 1.14% |
| 2015 FY | -5.46 Million USD | -18.4% |
| 2015 Q1 | -1.27 Million USD | 8.58% |
| 2015 Q4 | -1.59 Million USD | -19.3% |
| 2015 Q3 | -1.33 Million USD | -6.57% |
| 2014 FY | -4.61 Million USD | -164.29% |
| 2014 Q4 | -1.38 Million USD | -21.19% |
| 2014 Q3 | -1.14 Million USD | 11.52% |
| 2014 Q2 | -1.29 Million USD | -65.96% |
| 2014 Q1 | -780.67 Thousand USD | 18.77% |
| 2013 Q3 | -494.79 Thousand USD | -10784.21% |
| 2013 Q4 | -961.05 Thousand USD | -94.23% |
| 2013 FY | -1.74 Million USD | -4666.26% |
| 2013 Q2 | -4546.00 USD | -259.37% |
| 2013 Q1 | -1265.00 USD | 93.89% |
| 2012 Q2 | -9108.00 USD | -949.31% |
| 2012 Q4 | -20.71 Thousand USD | -250.14% |
| 2012 FY | -36.61 Thousand USD | -626.84% |
| 2012 Q1 | -868.00 USD | 82.57% |
| 2012 Q3 | -5917.00 USD | 35.04% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | -5037.00 USD | 0.0% |
| 2011 Q3 | -19.00 USD | 0.0% |
| 2011 Q4 | -4981.00 USD | -26115.79% |
| 2011 Q2 | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -277.742% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 71.735% |
| Nascent Biotech, Inc. | -2.22 Million USD | -126.222% |
| Rebus Holdings, Inc. | -664 Thousand USD | -659.711% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 106.163% |
| Qrons Inc. | -643.67 Thousand USD | -683.698% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1194.885% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 90.912% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1114.137% |
| Skye Bioscience, Inc. | -13.67 Million USD | 63.103% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 92.973% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 202.638% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1827.391% |
| SQZ Biotechnologies Company | -75.82 Million USD | 93.347% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -76.968% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -228.406% |
| Mesoblast Limited | -84.14 Million USD | 94.005% |
| Marizyme, Inc. | -34.08 Million USD | 85.201% |
| Genus plc | 6.4 Million USD | 178.82% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 151.778% |
| Pharming Group N.V. | -4.87 Million USD | -3.38% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -153.941% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -441.614% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 39.587% |
| ContraFect Corporation | -56.88 Million USD | 91.133% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -10.753% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -259.809% |
| IMV Inc. | -38.67 Million USD | 86.956% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -83.38% |
| MultiCell Technologies, Inc. | -722.81 USD | -697798.895% |
| ONE Bio Corp. | 13.68 Million USD | 136.871% |
| Accustem Sciences Inc. | -3.74 Million USD | -34.648% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 91.449% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -944.272% |
| Q BioMed Inc. | -3.44 Million USD | -46.403% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 242.5% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -91.986% |
| Biomind Labs Inc. | -1 Million USD | -399.65% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 90.824% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -73.873% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 24.12% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -170.573% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -16741.89% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 68.213% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -161.019% |
| GB Sciences, Inc. | -1.42 Million USD | -255.118% |
| Alpha Cognition Inc. | -9.7 Million USD | 48.025% |
| HST Global, Inc. | -140.9 Thousand USD | -3480.009% |
| CSL Limited | 3.7 Billion USD | 100.136% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -348.436% |
| Halberd Corporation | -75.05 Thousand USD | -6621.496% |
| Enzolytics Inc. | -2.14 Million USD | -134.758% |
| Agentix Corp. | -1.37 Million USD | -267.739% |
| Resverlogix Corp. | -12.74 Million USD | 60.432% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -59.219% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.813% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -383.188% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -72.789% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -219.401% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -48.15% |
| AVAX Technologies, Inc. | 6.69 Million USD | 175.371% |
| Zenith Capital Corp. | -8.94 Million USD | 43.593% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.787% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -28856.334% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -105.451% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2841.226% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -151.626% |
| Kadimastem Ltd | -3.04 Million USD | -65.923% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -412.623% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -301.631% |
| BioStem Technologies, Inc. | -7.77 Million USD | 35.152% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2679.559% |
| LadRx Corporation | -3.82 Million USD | -31.929% |
| Cell Source, Inc. | -4.32 Million USD | -16.626% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -634.33% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -634.33% |
| NovAccess Global Inc. | -2.46 Million USD | -104.498% |
| Affymax, Inc. | -15.04 Million USD | 66.473% |
| Itoco Inc. | -919.14 Thousand USD | -448.826% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -19.018% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -350.803% |
| Mobile Lads Corp. | -554.55 Thousand USD | -809.653% |
| CytoDyn Inc. | -18.05 Million USD | 72.065% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -19941.649% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -2192.134% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -793.267% |
| SYBLEU INC | -149.18 Thousand USD | -3281.474% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -177.731% |
| International Stem Cell Corporation | -663 Thousand USD | -660.857% |
| Bioxytran, Inc. | -3.82 Million USD | -32.049% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -9482.984% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -24700.801% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 86.09% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -211.773% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -585.545% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -62.15% |
| Neutra Corp. | -229.48 Thousand USD | -2098.166% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 71.238% |
| PureTech Health plc | -146.19 Million USD | 96.55% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 76.528% |
| IXICO plc | -1.43 Million USD | -251.043% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 46.85% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 95.859% |
| CSL Limited | 3.81 Billion USD | 100.132% |
| Cellectis S.A. | -108.85 Million USD | 95.366% |